Advancing Research and Development of Anti-infectives for Children: A Clinical Development Perspective
AM Buchanan, A Bekker, H Chandasana… - International Journal of …, 2024 - Elsevier
The HIV treatment landscape for adults has progressed dramatically in recent decades;
however, paediatric populations continue to experience delayed and limited access to …
however, paediatric populations continue to experience delayed and limited access to …
Population Pharmacokinetic Modeling of Abacavir/Dolutegravir/Lamivudine to Support a Fixed-Dose Combination in Children with HIV-1
H Chandasana, SC van Dijkman, R Mehta… - Infectious Diseases and …, 2024 - Springer
Introduction Once-daily fixed-dose combinations (FDC) containing abacavir (ABC),
dolutegravir (DTG), and lamivudine (3TC) have been approved in the US for adults and …
dolutegravir (DTG), and lamivudine (3TC) have been approved in the US for adults and …
Population pharmacokinetics of Dolutegravir in African Children: results from the CHAPAS-4 trial
H Waalewijn, RE Wasmann, A Bamford… - Journal of the …, 2024 - academic.oup.com
We characterized population pharmacokinetics in 42 African children receiving once-daily
25 mg (14 to< 20 kg) or 50 mg (> 20 kg) dolutegravir. Coadministration with emtricitabine …
25 mg (14 to< 20 kg) or 50 mg (> 20 kg) dolutegravir. Coadministration with emtricitabine …
Paediatric antiretroviral therapy challenges with emerging integrase resistance
A Bamford, L Hamzah, A Turkova - Current Opinion in HIV and AIDS - journals.lww.com
The antiretroviral treatment gap between adults and children persists. The potential benefits
from rollout of new paediatric DTG-based fixed-dose combination ART for first-line treatment …
from rollout of new paediatric DTG-based fixed-dose combination ART for first-line treatment …
Bridging dolutegravir clinical viral response across doses and formulations using model-based exposure-response analysis in pediatrics
H Chandasana, S Hayes, AM Buchanan, C Brothers… - AIDS, 2022 - journals.lww.com
Objective: Dolutegravir (DTG) is a once-daily HIV-1 integrase inhibitor approved for the
treatment of HIV-1 infection in adults and children from 4 weeks of age. The posology of DTG …
treatment of HIV-1 infection in adults and children from 4 weeks of age. The posology of DTG …